Cargando…
A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age
Since the last Italian cost-utility assessment of palivizumab in 2009, new data on the burden of respiratory syncytial virus (RSV) and an International Risk Scoring Tool (IRST) have become available. The objective of this study was to provide an up-to-date cost-utility assessment of palivizumab vers...
Autores principales: | Keary, Ian P., Ravasio, Roberto, Fullarton, John R., Manzoni, Paolo, Lanari, Marcello, Paes, Bosco A., Carbonell-Estrany, Xavier, Baraldi, Eugenio, Tarride, Jean-Éric, Rodgers-Gray, Barry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414677/ https://www.ncbi.nlm.nih.gov/pubmed/37561741 http://dx.doi.org/10.1371/journal.pone.0289828 |
Ejemplares similares
-
Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons
por: Anderson, Evan J., et al.
Publicado: (2017) -
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015) -
Burden of respiratory syncytial virus hospitalisation among infants born at 32–35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies
por: Lanari, M., et al.
Publicado: (2020) -
Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants
por: Blanken, Maarten O., et al.
Publicado: (2018) -
Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017
por: Kim, Doyoung, et al.
Publicado: (2019)